Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

2-Fluoro-L-histidine, an Inhibitor of Enzyme Induction

DAVID C. KLEIN, KENNETH L. KIRK, JOAN L. WELLER, TAKAMI OKA, ANDREW PARFITT and IDA S. OWENS
Molecular Pharmacology September 1976, 12 (5) 720-730;
DAVID C. KLEIN
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENNETH L. KIRK
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOAN L. WELLER
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAMI OKA
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREW PARFITT
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IDA S. OWENS
Section on Physiological Controls, Laboratory of Biomedical Sciences, and Section on Developmental Pharmacology, Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development; and Section on Biochemical Mechanisms, Laboratory of Chemistry, and Section on Intermediary Metabolism, Laboratory of Biochemistry and Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effect of a new amino acid analogue, 2-fluoro-L-histidine, on the stimulation of certain enzyme activities in the rat pineal gland, mouse mammary gland, a hepatoma cell line, and rat liver explants was investigated. This compound inhibited the isoproterenol stimulation of pineal N-acetyltransferase activity in vivo, and in organ culture it blocked the isoproterenol, norepinephrine, and N6,2'-O-dibutyryladenosine 3',5'-monophosphate stimulation of this enzyme. Inhibitory effects of 2-fluorohistidine on the steroid induction of tyrosine aminotransferase in liver explants and on benz[a]anthracene induction of aryl hydrocarbon hydroxylase in established hepatoma cell line cultures were also observed. 2-Fluorohistidine did not block the spontaneous increase in ornithine decarboxylase activity in explants of mouse mammary gland, but did partially block the spontaneous increase of this enzyme in cultured pineal glands. In cultured pineal glands, no evidence was found for direct competitive or noncompetitive inhibition of N-acetyltransferase by 2-fluorohistidine, for the existence of any inhibitory effect on N-acetyltransferase activity in 2-fluorohistidine-treated glands, or for rapid irreversible toxic effects of this analogue. Unlike cycloheximide, which blocks the stimulation of pineal N-acetyltransferase activity by blocking protein synthesis, 2-fluorohistidine did not substantially inhibit the incorporation of [3H]leucine into protein. However, the incorporation of [14C]histidine is reduced by 50-90% in pineal glands treated with 2-fluorohistidine. This, together with the observation that the inhibitory effect of the analogue on enzyme induction and on [14C]histidine incorporation was reversed by an equal concentration of histidine, suggests to us that 2-fluorohistidine may act by competing with histidine in a metabolic pathway, perhaps protein synthesis.

ACKNOWLEDGMENTS We thank Drs. C. R. Creveling and Louis A. Cohen for their valuable discussions and advice during the course of this investigation. Special acknowledgment is made of the generous contributions of Dr. Howard Eisen, who conducted the liver explant culture experiment.

  • Copyright © 1976 by Academic Press, Inc.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 12, Issue 5
1 Sep 1976
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
2-Fluoro-L-histidine, an Inhibitor of Enzyme Induction
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

2-Fluoro-L-histidine, an Inhibitor of Enzyme Induction

DAVID C. KLEIN, KENNETH L. KIRK, JOAN L. WELLER, TAKAMI OKA, ANDREW PARFITT and IDA S. OWENS
Molecular Pharmacology September 1, 1976, 12 (5) 720-730;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

2-Fluoro-L-histidine, an Inhibitor of Enzyme Induction

DAVID C. KLEIN, KENNETH L. KIRK, JOAN L. WELLER, TAKAMI OKA, ANDREW PARFITT and IDA S. OWENS
Molecular Pharmacology September 1, 1976, 12 (5) 720-730;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics